Wolverine Legal Status, FDA 503A Category, and Compounding Access

Wolverine legal status: where BPC-157 TB-500 access stands now and where it is heading

The most important fact about the Wolverine legal status is also the most forward-looking one: the compounding status of both peptides in the BPC-157 TB-500 blend is under active FDA review, and access could change. FDA's Pharmacy Compounding Advisory Committee (PCAC) has a meeting scheduled for July 23-24, 2026, and both BPC-157 and TB-500 are on its published agenda as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[11][12]. That is a scheduled evaluation — a step in the process, not a decision. Nothing has been reclassified, listed, or removed, and no outcome should be assumed from a meeting that has not happened.

What is settled today is the current category. As of the most recent confirmable FDA action, both constituents are in 503A "Category 2" — bulk substances FDA has identified as potentially presenting significant safety risks — effective with FDA's September 29, 2023 update to the nominated-substances list ^[13][14]. Category 2 substances are not covered by FDA's enforcement-discretion policy for 503A compounding, which means compounding-pharmacy access to these peptides is currently restricted ^[13]. Neither peptide is an FDA-approved drug, and the blend has no approved therapeutic indication. This page is general information about the regulatory landscape, not medical or legal advice.

Both components are Category 2 — and both are on the July 2026 PCAC agenda

There is no component carve-out in the BPC-157 TB-500 blend. Both legs are in the same regulatory position.

BPC-157 (which FDA evaluated as "BPC-157 (free base)" and "BPC-157 acetate") was placed in Category 2 effective September 29, 2023, with FDA citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[13]. TB-500 — which FDA lists as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — was placed in Category 2 on the same date, with FDA citing potential immunogenicity for certain routes and a lack of important safety information ^[14]. FDA's own list entry establishes the relationship between the marketed name and the fragment: TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 ^[14].

Both are now scheduled for the same review. The July 23-24, 2026 PCAC agenda lists both BPC-157 and TB-500 (alongside other peptides) as candidates being considered for the 503A Bulks List ^[11][12]. A PCAC discussion is advisory; it informs FDA, but it is not itself a listing decision. The honest read is momentum, not a verdict: these peptides are moving through evaluation, and 503A access for them may expand in 2026 — but that is a possibility under review, not a dated outcome.

How legally compounded peptide access works

Setting aside any single substance, it helps to understand how lawful compounded-medication access works in the United States. Drug compounding is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, performed pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[15].

The lawful pathway runs in a fixed order. First, a patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate ^[16]. Telehealth here is simply one front-end channel to that evaluation and prescription; it does not change which substances may be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[16]. Second, if appropriate and lawful, the prescriber issues a valid, patient-specific prescription. Third, the prescription is dispensed by a state-licensed 503A compounding pharmacy, or sourced for office or batch use from an FDA-registered 503B outsourcing facility ^[16].

The critical caveat sits at the ingredient level. A compounder may use a bulk drug substance only if it is the subject of an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[15]. A substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[13]. That is precisely why both legs of this blend matter for access: as Category 2 substances today, neither is eligible for routine 503A compounding, regardless of the consultation channel through which a prescription might be sought ^[13][14]. This is general regulatory information, not a route to obtain any restricted substance.